期刊
JOURNAL OF MOLECULAR NEUROSCIENCE
卷 48, 期 3, 页码 667-673出版社
HUMANA PRESS INC
DOI: 10.1007/s12031-012-9815-4
关键词
PACAP; Colon cancer; Lung cancer; Heart disorder; PAC1 receptor
资金
- OTKA [K72592, 75965, CNK78480]
- TAMOP [4.2.1.B-10/2/KONV-2010-002, 4.2.2.B-10/1-2010-0029]
- Bolyai Scholarship
- Richter Foundation
- PTE AOK Research Grant [KA-4039/10-26]
- PTE-MTA Lendulet Program
Pituitary adenylate cyclase activating polypeptide (PACAP) is a pleiotropic and multifunctional neuropeptide having important roles in various physiological processes. Recent trends in PACAP research point to the clinical introduction of PACAP or its analogs/fragments possibly in the near future. Recently, we have shown the presence of PACAP in human plasma, milk, placenta, and follicular fluid samples. However, relatively few data are available on PACAP in human tissues from patients with different disorders. The aim of the present study was to determine, by radioimmunoassay, the tissue level of PACAP38-like immunoreactivity (LI) and PACAP27-LI in different primary non-small cell lung cancer, colon tumor samples, and in cardiac muscle samples from patients suffering from ischemic heart disease and valvular disorders. We also labeled the PAC1 receptors in human cardiac cells. All samples showed significantly higher PACAP38-LI compared with PACAP27-LI. We found significantly lower levels of PACAP38-LI and PACAP27-LI in tumoral and peripheral samples compared with normal healthy tissue in both lung and colon cancers. Further investigations are necessary to describe the exact function of PACAP in oncogenesis. We showed that PACAP38-LI and PACAP27-LI are significantly higher in ischemic heart diseases compared with valvular abnormalities, suggesting that PACAP might play a role in ischemic heart disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据